Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment and outcome of invasive Aspergillus infections in allogeneic BMTrecipients
Autore:
Jantunen, E; Ruutu, P; Piilonen, A; Volin, L; Parkkali, T; Ruutu, T;
Indirizzi:
Kuopio Univ Hosp, Dept Med, Kuopio 70211, Finland Kuopio Univ Hosp Kuopio Finland 70211 p, Dept Med, Kuopio 70211, Finland Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland Univ Helsinki Helsinki Finland , Cent Hosp, Dept Med, Helsinki, Finland Natl Publ Hlth Inst, Helsinki, Finland Natl Publ Hlth Inst Helsinki Finland Publ Hlth Inst, Helsinki, Finland Univ Helsinki, Cent Hosp, Dept Radiol, Helsinki, Finland Univ Helsinki Helsinki Finland ent Hosp, Dept Radiol, Helsinki, Finland
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 7, volume: 26, anno: 2000,
pagine: 759 - 762
SICI:
0268-3369(200010)26:7<759:TAOOIA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
MARROW TRANSPLANT RECIPIENTS; COLONY-STIMULATING FACTOR; B COLLOIDAL DISPERSION; PULMONARY ASPERGILLOSIS; AMPHOTERICIN-B; FUNGAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS; NEUTROPENIC PATIENTS; ACUTE-LEUKEMIA; CLINICAL-EXPERIENCE;
Keywords:
Aspergillus infection; treatment; outcome; allogeneic BMT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Jantunen, E Kuopio Univ Hosp, Dept Med, POB 1777, Kuopio 70211, Finland Kuopio Univ Hosp POB 1777 Kuopio Finland 70211 70211, Finland
Citazione:
E. Jantunen et al., "Treatment and outcome of invasive Aspergillus infections in allogeneic BMTrecipients", BONE MAR TR, 26(7), 2000, pp. 759-762

Abstract

The outcome of invasive aspergillosis (IA) has been considered poor in allogeneic BMT recipients. We analyzed retrospectively the treatment and outcome of IA diagnosed during life in a recent cohort of 20 allogeneic BMT recipients. All patients were initially treated with amphotericin B (AmB) (conventional 16, liposomal 4), Due to toxicity, conventional AmB was changed toa liposomal preparation in 10 patients. Five patients also received itraconazole and three underwent surgery. Of 19 evaluable patients, two patients achieved a complete response and a partial response was observed in five patients (response rate 37%), The median survival was 37 days after the diagnosis. Only two patients (10%) were cured. The prognosis of allogeneic BMT recipients with IA has remained poor. Although treatment responses are common, immunosuppression aggravated by GVHD and its treatment, as well as the commonly disseminated presentation of IA, seem to be major obstacles to the success of therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 09:23:10